{"id":111997,"date":"2024-07-25T14:46:23","date_gmt":"2024-07-25T13:46:23","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=insight&p=111997"},"modified":"2024-07-29T17:31:46","modified_gmt":"2024-07-29T16:31:46","slug":"trending-at-asco2024","status":"publish","type":"insight","link":"https:\/\/touchoncology.com\/insight\/trending-at-asco2024\/","title":{"rendered":"Trending at #ASCO2024"},"content":{"rendered":"
The annual ASCO2024 meeting was packed as always with the latest trial data and treatment advances in oncology. For those unable to visit Chicago this year, Twitter provides a glimpse into the impactful presentations and data. Here are some of the top trending abstracts and topics from this year\u2019s meeting:<\/span><\/p>\n First results from the preplanned interim analysis <\/span>from the phase III <\/span>CheckMate-9DW trial (<\/span>NCT04039607<\/span><\/a><\/span>)<\/span> showed <\/span>nivolumab in combination with ipilimumab demonstrate a <\/span>significant overall survival benefit <\/span>compared to <\/span>lenvatinib or sorafenib<\/b> in the 1st-line treatment of patients with <\/span>unresectable hepatocellular carcinoma (HCC).<\/span><\/p>\n The full abstract is available here<\/span><\/a>.<\/span><\/p>\n \u00a0Results from the DESTINY-Breast06 <\/span>phase 3 trial<\/span> found trastuzumab deruxtecan demonstrated clinically meaningful progression-free survival (PFS) improvement in patients with hormone receptor (HR)\u2013positive, HER2-low metastatic breast cancer following endocrine therapy.\u00a0<\/span><\/p>\n The trial results establish <\/span>trastuzumab deruxtecan<\/span> \u201cas an effective new treatment option for patients with HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one line or more of endocrine-based therapy and no prior chemotherapy,\u201d according to study presenter Giuseppe Curigliano, MD, PhD, of the University of Milan and European Institute of Oncology in Italy.<\/span><\/p>\n View the full abstract here.<\/span><\/a><\/span><\/p>\n Results from the phase III LAURA trial demonstrated that osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non-small-cell lung cancer (NSCLC) following definitive chemoradiotherapy.<\/span><\/p>\n Lead author Suresh Ramalingham commented: \u201cThere are currently no approved targeted treatments specifically for unresectable stage III <\/span>EGFR<\/span><\/i>-mutated NSCLC. The LAURA study showed a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with unresectable <\/span>EGFR<\/span><\/i>-mutated NSCLC following definitive chemoradiotherapy. With the superior efficacy results along with the robust magnitude of benefit in the LAURA study, osimertinib provides a solution to a large unmet need for this patient population. These data suggest that osimertinib will become a new standard of care for patients with unresectable stage III <\/span>EGFR<\/span><\/i>-mutated NSCLC following definitive chemoradiotherapy\u201d.<\/span><\/p>\nCheckMate-9DW trial<\/h1>\n
DESTINY-Breast06<\/span><\/h1>\n
LAURA trial<\/span><\/h1>\n